Perimenopausal period and mood disorders
The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-04-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/6113 |
id |
doaj-3bcd5b432d2c49268fce91945f068289 |
---|---|
record_format |
Article |
spelling |
doaj-3bcd5b432d2c49268fce91945f0682892021-07-28T13:29:49ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-04-010423023910.21518/2079-701X-2021-4-230-2395554Perimenopausal period and mood disordersN. V. Pizova0N. A. Pizov1A. V. Pizov2Yaroslavl State Medical UniversityYaroslavl State Medical UniversityYaroslavl State Pedagogical University named after K.D. UshinskyThe article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.https://www.med-sovet.pro/jour/article/view/6113perimenopauseneuropsychiatric disordersmood disordersdepressionstresshormonal backgroundtofisopam |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
N. V. Pizova N. A. Pizov A. V. Pizov |
spellingShingle |
N. V. Pizova N. A. Pizov A. V. Pizov Perimenopausal period and mood disorders Медицинский совет perimenopause neuropsychiatric disorders mood disorders depression stress hormonal background tofisopam |
author_facet |
N. V. Pizova N. A. Pizov A. V. Pizov |
author_sort |
N. V. Pizova |
title |
Perimenopausal period and mood disorders |
title_short |
Perimenopausal period and mood disorders |
title_full |
Perimenopausal period and mood disorders |
title_fullStr |
Perimenopausal period and mood disorders |
title_full_unstemmed |
Perimenopausal period and mood disorders |
title_sort |
perimenopausal period and mood disorders |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2021-04-01 |
description |
The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects. |
topic |
perimenopause neuropsychiatric disorders mood disorders depression stress hormonal background tofisopam |
url |
https://www.med-sovet.pro/jour/article/view/6113 |
work_keys_str_mv |
AT nvpizova perimenopausalperiodandmooddisorders AT napizov perimenopausalperiodandmooddisorders AT avpizov perimenopausalperiodandmooddisorders |
_version_ |
1721273469524508672 |